Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new lens make glasses obsolete after cataract surgery?

NCT ID NCT07790887

Disease control Sponsor: Vance Thompson Vision Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests the TECNIS PureSee, an extended depth of focus lens implanted during cataract surgery, in 50 adults with cataracts in both eyes. The goal is to see how well the lens restores vision at distance, intermediate, and near ranges, and whether it allows people to go without glasses for daily tasks. Researchers will measure visual acuity and use a questionnaire to track spectacle independence and any visual disturbances after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TECNIS PureSee extended depth of focus intraocular lens (IOL), a device implanted during cataract surgery
What this could lead to
If it works, this lens could help people see clearly at multiple distances after cataract surgery, reducing the need for glasses.
What could go wrong
This is a small, single-arm study without a comparison group, so results may not apply broadly. Some people may still experience visual disturbances or need glasses for certain tasks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥40 years with bilateral visually significant cataracts electing to undergo cataract surgery 2. Calculated IOL power within the available PureSee power range 3. Both eyes targeted for plano (first minus recommended) in both eyes 4. Preoperative corneal astigmatism ≤0.75 D for non-toric PureSee, or within the treatment range of the PureSee Toric platform 5. Potential postoperative best-corrected distance visual acuity of 20/25 or better in each eye 6. Willing and able to comply with the scheduled visits and study procedures Exclusion Criteria: 1. Prior intraocular or corneal refractive surgery in the operative eye(s) 2. Irregular corneal astigmatism, keratoconus, pellucid marginal degeneration, or other ectatic disease 3. Clinically significant macular pathology, advanced glaucoma with field loss, amblyopia, or any concurrent ocular condition that would limit BCVA at the discretion of the investigator 4. Pupil abnormalities, zonular instability, pseudoexfoliation, or any condition predisposing to intraoperative or postoperative IOL instability 5. History of ocular trauma or uveitis 6. Uncontrolled systemic disease that in the opinion of the investigator would interfere with study participation or healing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Vance Thompson Vision

    Sioux Falls, South Dakota, 57108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.